186 related articles for article (PubMed ID: 19682517)
1. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.
Yurkovetskiy AV; Fram RJ
Adv Drug Deliv Rev; 2009 Nov; 61(13):1193-202. PubMed ID: 19682517
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
Walsh MD; Hanna SK; Sen J; Rawal S; Cabral CB; Yurkovetskiy AV; Fram RJ; Lowinger TB; Zamboni WC
Clin Cancer Res; 2012 May; 18(9):2591-602. PubMed ID: 22392910
[TBL] [Abstract][Full Text] [Related]
3. Reduction-responsive amphiphilic polymeric prodrugs of camptothecin-polyphosphoester for cancer chemotherapy.
Jin H; Sun M; Shi L; Zhu X; Huang W; Yan D
Biomater Sci; 2018 May; 6(6):1403-1413. PubMed ID: 29595843
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
5. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
[TBL] [Abstract][Full Text] [Related]
6. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker.
Conover CD; Greenwald RB; Pendri A; Gilbert CW; Shum KL
Cancer Chemother Pharmacol; 1998; 42(5):407-14. PubMed ID: 9771956
[TBL] [Abstract][Full Text] [Related]
7. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies.
Rowinsky EK; Rizzo J; Ochoa L; Takimoto CH; Forouzesh B; Schwartz G; Hammond LA; Patnaik A; Kwiatek J; Goetz A; Denis L; McGuire J; Tolcher AW
J Clin Oncol; 2003 Jan; 21(1):148-57. PubMed ID: 12506184
[TBL] [Abstract][Full Text] [Related]
10. [CPT-11: new drug for metastatic colorectal cancer].
Barone C; Pozzo C; Cassano A
Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
[No Abstract] [Full Text] [Related]
11. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.
Schoemaker NE; van Kesteren C; Rosing H; Jansen S; Swart M; Lieverst J; Fraier D; Breda M; Pellizzoni C; Spinelli R; Grazia Porro M; Beijnen JH; Schellens JH; ten Bokkel Huinink WW
Br J Cancer; 2002 Sep; 87(6):608-14. PubMed ID: 12237769
[TBL] [Abstract][Full Text] [Related]
13. [CPT-11 (irinotecan)--evidence from molecular and pharmacological studies and clinical applications].
Isobe T; Ishikawa N; Oguri T
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1267-78. PubMed ID: 10945026
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Takagi T; Saotome T
Leuk Lymphoma; 2001 Aug; 42(4):577-86. PubMed ID: 11697485
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
de Forni M; Bugat R; Chabot GG; Culine S; Extra JM; Gouyette A; Madelaine I; Marty ME; Mathieu-Boué A
Cancer Res; 1994 Aug; 54(16):4347-54. PubMed ID: 8044782
[TBL] [Abstract][Full Text] [Related]
16. Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Nguyen F; Guan P; Guerrero DT; Kolla V; Naraparaju K; Perry LM; Soberman D; Pressly BB; Alferiev IS; Chorny M; Brodeur GM
Cancer Res; 2020 Oct; 80(19):4258-4265. PubMed ID: 32839252
[TBL] [Abstract][Full Text] [Related]
17. CPT-11: the European clinical development.
Terret C; Couteau C; Armand JP
J Infus Chemother; 1996; 6(3):152-7. PubMed ID: 9229329
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of a macromolecular camptothecin conjugate with dual phase drug release.
Yurkovetskiy AV; Hiller A; Syed S; Yin M; Lu XM; Fischman AJ; Papisov MI
Mol Pharm; 2004; 1(5):375-82. PubMed ID: 16026008
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
Lavelle F; Bissery MC; André S; Roquet F; Riou JF
Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
[TBL] [Abstract][Full Text] [Related]
20. Polymer-bound camptothecin: initial biodistribution and antitumour activity studies.
Caiolfa VR; Zamai M; Fiorino A; Frigerio E; Pellizzoni C; d'Argy R; Ghiglieri A; Castelli MG; Farao M; Pesenti E; Gigli M; Angelucci F; Suarato A
J Control Release; 2000 Mar; 65(1-2):105-19. PubMed ID: 10699275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]